Peptide T (TFA)

Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

Product Specifications

CAS Number

[1610056-01-3]

UNSPSC

12352209

Target

HIV

Type

Peptides

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Peptide_T_TFA.html

Solubility

10 mM in DMSO

Smiles

O=C(O)C(F)(F)F.OC(C=C1)=CC=C1C[C@@H](C(N[C@H](C(O)=O)[C@H](O)C)=O)NC([C@H](CC(N)=O)NC([C@H](C(O)C)NC([C@H]([C@H](O)C)NC([C@H]([C@H](O)C)NC([C@H](CO)NC([C@@H](N)C)=O)=O)=O)=O)=O)=O

Molecular Formula

C37H56F3N9O18

Molecular Weight

971.89

References & Citations

[1]Ruff MR, et al. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment. Lancet. 1987 Sep 26;2 (8561) :751.|[2]Ruff MR, et al. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5) . Antiviral Res. 2001 Oct;52 (1) :63-75.|[3]Raychaudhuri SP, et al. Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines. Int J Immunopharmacol. 1999 Sep;21 (9) :609-15.|[4]Sáez-Torres I, et al. Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol. 2000 Jul;121 (1) :151-6.